Alnylam Pharmaceuticals (ALNY) Work In Process (2018 - 2026)

Alnylam Pharmaceuticals has reported Work In Process for 9 years, with the latest figure at $65.5 million in Q1 2026.

• For the quarter ending Q1 2026, Work In Process rose 21.24% year-over-year to $65.5 million; the trailing twelve-month figure through Mar 2026 stood at $65.5 million (up 21.24% YoY), and the FY2025 full-year result was $65.1 million, changed 0.22% from the prior year.
• Work In Process for Q1 2026 stood at $65.5 million, up from $65.1 million in the prior quarter.
• The five-year high for Work In Process was $116.7 million in Q2 2023, with the low at $35.5 million in Q3 2025.
• Historically, Work In Process has averaged $79.0 million across 5 years, with a median of $76.1 million in 2024.
• Annual changes were most pronounced in 2022 — Work In Process surged 295.84% — and 2025, when it plunged 49.18%.
• Alnylam Pharmaceuticals' Work In Process stood at $113.8 million in 2022, then slumped by 32.36% to $77.0 million in 2023, then dropped by 15.57% to $65.0 million in 2024, then grew by 0.22% to $65.1 million in 2025, then advanced by 0.51% to $65.5 million in 2026.
• The last three Work In Process figures came in at $65.5 million (Q1 2026), $65.1 million (Q4 2025), and $35.5 million (Q3 2025), per Business Quant data.